Trimethoprim for Chest Infections: Use, Spectrum & Resistance

Trimethoprim is a dihydrofolate reductase inhibitor used primarily for urinary tract infections. Its role in lower respiratory tract infections (LRTI) is limited and context-dependent.

Typical Respiratory Pathogens & Susceptibility

• Streptococcus pneumoniae: Variable resistance (often 20–40%); not reliable as monotherapy.
• Haemophilus influenzae: Moderate susceptibility; beta-lactamase production doesn't affect trimethoprim, but resistance is common.
• Moraxella catarrhalis: Often susceptible, but nearly all produce beta-lactamase (irrelevant to trimethoprim).
• Atypical pathogens (Mycoplasma, Chlamydia, Legionella): Intrinsically resistant.

Clinical Use in LRTI

• Rarely used as first-line monotherapy for community-acquired pneumonia (CAP) or acute bronchitis.
• Component of co-trimoxazole (trimethoprim-sulfamethoxazole), which has broader coverage and is used for Pneumocystis jirovecii pneumonia (PCP) in immunocompromised hosts.
• Sometimes used for COPD exacerbations if culture-guided and susceptible.

Key Limitations

• Poor activity against S. pneumoniae in many regions.
• No coverage for atypicals or viruses.
• Risk of hyperkalemia, especially with ACE inhibitors/ARBs, potassium-sparing diuretics, or renal impairment.
• Folate antagonism—caution in pregnancy, megaloblastic anemia.

Preferred Alternatives for CAP

• Amoxicillin or amoxicillin-clavulanate
• Doxycycline / macrolide (azithromycin, clarithromycin)
• Respiratory fluoroquinolone (levofloxacin, moxifloxacin) for comorbidities or failure

Trimethoprim alone is not a standard empirical choice for chest infections. If prescribed, it should be based on culture and susceptibility data.